3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5h)-furanone has been researched along with diclofenac in 2 studies
| Studies (3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5h)-furanone) | Trials (3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5h)-furanone) | Recent Studies (post-2010) (3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5h)-furanone) | Studies (diclofenac) | Trials (diclofenac) | Recent Studies (post-2010) (diclofenac) |
|---|---|---|---|---|---|
| 25 | 0 | 2 | 8,874 | 1,874 | 3,616 |
| Protein | Taxonomy | 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5h)-furanone (IC50) | diclofenac (IC50) |
|---|---|---|---|
| Aldo-keto reductase family 1 member B10 | Homo sapiens (human) | 1.9 | |
| Prostaglandin G/H synthase 1 | Bos taurus (cattle) | 0.003 | |
| Prostaglandin G/H synthase 1 | Ovis aries (sheep) | 1.3376 | |
| Interleukin-8 | Homo sapiens (human) | 0.008 | |
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | 0.0415 | |
| Sodium- and chloride-dependent GABA transporter 1 | Rattus norvegicus (Norway rat) | 0.5 | |
| C-X-C chemokine receptor type 1 | Homo sapiens (human) | 0.012 | |
| Sodium- and chloride-dependent GABA transporter 2 | Rattus norvegicus (Norway rat) | 0.5 | |
| Sodium- and chloride-dependent GABA transporter 3 | Rattus norvegicus (Norway rat) | 0.5 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 0.4165 | |
| Prostaglandin G/H synthase 2 | Rattus norvegicus (Norway rat) | 0.5 | |
| Sodium- and chloride-dependent betaine transporter | Rattus norvegicus (Norway rat) | 0.5 | |
| Prostaglandin G/H synthase 2 | Ovis aries (sheep) | 1.6867 | |
| Prostaglandin G/H synthase 2 | Mus musculus (house mouse) | 0.0502 | |
| Solute carrier family 22 member 6 | Homo sapiens (human) | 4 | |
| Prostaglandin G/H synthase 1 | Rattus norvegicus (Norway rat) | 0.5 | |
| P2Y purinoceptor 12 | Rattus norvegicus (Norway rat) | 0.02 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brideau, C; Chan, CC; Charleson, S; Cromlish, W; Ethier, D; Evans, JF; Ford-Hutchinson, AW; Gauthier, JY; Gordon, R; Gresser, M; Guay, J; Kargman, S; Kennedy, B; Leblanc, Y; Léger, S; Mancini, J; O'Neill, GP; Ouellet, M; Percival, MD; Perrier, H; Prasit, P; Riendeau, D; Rodger, I; Wang, Z; Zamboni, R | 1 |
| Asif, M; Husain, A; Iqbal, MA; Iram, F; Khan, SA | 1 |
1 review(s) available for 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5h)-furanone and diclofenac
| Article | Year |
|---|---|
Insights into the chemistry and therapeutic potential of furanones: A versatile pharmacophore.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antifungal Agents; Antineoplastic Agents; Antiviral Agents; Humans; Molecular Structure | 2019 |
1 other study(ies) available for 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5h)-furanone and diclofenac
| Article | Year |
|---|---|
The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor.
Topics: Administration, Oral; Animals; Biological Availability; CHO Cells; Cricetinae; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Enzyme Inhibitors; Humans; Indomethacin; Inhibitory Concentration 50; Isoenzymes; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Rats; Sulfones | 1999 |